-
Mashup Score: 0Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal - 9 month(s) ago
Show More *M.D. and E.E.V. contributed equally to this work as senior authors. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment - 10 month(s) ago
Background: Circulating tumor DNA (ctDNA) is used to select initial targeted therapy, identify mechanisms of therapeutic resistance, and measure minimal residual disease (MRD) after treatment. Our objective was to review private and Medicare coverage policies for ctDNA testing. Methods: Policy Reporter was used to identify coverage policies (as of February 2022) from private payers and Medicare…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Private Payer & Medicare Coverage Policies for Use of #ctDNA Tests in #Cancer Diagnostics & Treatment: https://t.co/7QH2Wqh15W #cactc #hpeonc @MDouglas_MS @meera_Ragavan @Chenchengclaire @Stacywgray @collin_Blakely @KathrynP_phd @ucsfpharmacy @ucsfprecision @ucsf @UCSF_TRANSPERS https://t.co/H5anh8bXmu
-
-
Mashup Score: 0The ASCO Post - 11 month(s) ago
Among 546 patients enrolled, 4.8% had a positive CTC assay result; among patients with hormone receptor–positive breast cancer, 5.1% had a positive CTC result; among those with hormone receptor–negative disease, 4.3% had a positive CTC result. After a median follow-up of 1.6 years, a positive CTC assay result was associated with a nearly 20-fold increased risk of breast cancer recurrence in…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer [12/8/17] @ASCOPost https://t.co/1A14bpi1Qg #bcsm #caprev #cactc
-
-
Mashup Score: 0JNCCN 360 - B-Cell Lymphomas - ASH 2022: POLARIX Trial Focuses on ctDNA for Risk Profiling in Diffuse Large B-Cell Lymphoma - 1 year(s) ago
By: Vanessa A. Carter, BS Posted: Friday, December 16, 2022 Alex F. Herrera, MD, of the City of Hope Comprehensive Cancer Center, Duarte, California, and colleagues are attempting to validate the prognostic value of circulating tumor DNA (ctDNA) in patients with treatment-naive diffuse large B-cell lymphoma (DLBCL)….
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASH22: POLARIX Trial Focuses on #ctDNA for Risk Profiling in Diffuse Large B-Cell #Lymphoma: https://t.co/Yp5OyLIcU1 #JNCCN360 #DLBCL #lymsm #cactc https://t.co/ikoLfPopOI
-
-
Mashup Score: 3
PURPOSE To examine the prevalence and dynamics of circulating tumor DNA (ctDNA) and its association with metastatic recurrence in patients with high-risk early-stage hormone receptor–positive breast cancer (HR+ BC) more than 5 years from diagnosis. METHODS We enrolled 103 patients with high-risk stage II-III HR+ BC diagnosed more than 5 years prior without clinical evidence of recurrence. We…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Featured in Best of #JCO #BreastCancer Edition: Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer https://t.co/HYLgR59oFt #BCSM #cactc #ctDNA
-
-
Mashup Score: 2JNCCN 360 - MM - Optimal Cutoff Value of Circulating Tumor Cells in Myeloma: Biomarker of Adverse Outcomes? - 2 year(s) ago
By: Joshua D. Madera, MS Posted: Monday, August 22, 2022 An increasing level of circulating tumor plasma cells (CTCs) may represent an independent high-risk factor once the cells surpass an optimal cutoff value for patients with multiple myeloma, according to the multicenter, randomized, phase II FORTE study published…
Source: jnccn360.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JNCCN: What is the Optimal Cutoff Value of #CirculatingTumorCells in #Myeloma: Biomarker of Adverse Outcomes? https://t.co/v0E3eMYnUK #…
-
What is the Optimal Cutoff Value of #CirculatingTumorCells in #Myeloma: Biomarker of Adverse Outcomes? https://t.co/v0E3eMYnUK #MMSM #cactc #JNCCN360 https://t.co/1aOpNPcJpb
-
-
Mashup Score: 3Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer - 2 year(s) ago
Tumor-resident intracellular bacteria enhance survival of circulating tumor cells by cytoskeleton reorganization. They promote metastasis but are not required for primary tumor growth in a murine breast cancer model.
Source: CellCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study reveals a conserved intracellular bacterial profile in murine & human #breastcancer, perturbation of which reduces metastasis; disrupting bacterial reorganization of the actin cytoskeleton in CTCs reduces their resistance to mechanical stress: https://t.co/SEFDQuoJYP #cactc
-
-
Mashup Score: 0Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study - 3 year(s) ago
Background: This study aimed to describe the aberrations of DNA damage repair genes and other important driving genes in Chinese patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating tumor (ctDNA) sequencing and to evaluate the associations between the clinical outcomes of multiple therapies and key genomic…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ONLINE FIRST: Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant #ProstateCancer: A Multicenter, Real-World Study: https://t.co/fhPFZvL1Gq #PCSM #cactc https://t.co/AHfQO9zfzu
-
-
Mashup Score: 1
Background: While the detection of the AR-V7 in CTCs is associated with resistance to abiraterone or enzalutamide (abi/enza) in men with metastatic castration resistant prostate cancer (mCRPC), it only accounts for a minority of this resistance. Neuroendocrine (NE) differentiation or chromosomal instability (CIN) may be additional mechanisms that mediate resistance. Methods: PROPHECY was a…
Source: Clinical Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data suggest that a high chromosomal instability and a neuroendocrine CTC phenotype are independently associated with worse survival in men with mCRPC treated with abiraterone or enzalutamide: https://t.co/AySpbHq0fX #PCSM #cactc
-
-
Mashup Score: 0SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer - The ASCO Post - 3 year(s) ago
Among 546 patients enrolled, 4.8% had a positive CTC assay result; among patients with hormone receptor–positive breast cancer, 5.1% had a positive CTC result; among those with hormone receptor–negative disease, 4.3% had a positive CTC result. After a median follow-up of 1.6 years, a positive CTC assay result was associated with a nearly 20-fold increased…
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer [12/8/17] @ASCOPost https://t.co/1A14bpi1Qg #bcsm #caprev #cactc
-
🤔 #JCO #CommentsAndControversies: Early Stage #LungCancer: Using ctDNA to Get Personal ➡️ https://t.co/y8xZNCcXYq #LCSM #cactc @eevokes @ChristineBestv1 https://t.co/HvOTeEcMvF